Aurora Investment Counsel Has $1.17 Million Stock Position in CONMED Co. (NYSE:CNMD)

Aurora Investment Counsel grew its holdings in shares of CONMED Co. (NYSE:CNMD) by 12.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,133 shares of the company’s stock after purchasing an additional 1,841 shares during the quarter. Aurora Investment Counsel owned about 0.06% of CONMED worth $1,173,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of CNMD. Raymond James Financial Inc. bought a new position in CONMED during the fourth quarter valued at about $18,248,000. Fisher Asset Management LLC raised its stake in shares of CONMED by 41.4% in the 4th quarter. Fisher Asset Management LLC now owns 417,430 shares of the company’s stock valued at $28,569,000 after acquiring an additional 122,140 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in CONMED in the 4th quarter worth approximately $5,790,000. Champlain Investment Partners LLC boosted its position in CONMED by 6.4% during the third quarter. Champlain Investment Partners LLC now owns 1,367,650 shares of the company’s stock worth $98,361,000 after purchasing an additional 81,970 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in CONMED by 44.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 223,142 shares of the company’s stock worth $15,029,000 after purchasing an additional 68,696 shares during the period.

CONMED Trading Down 1.1 %

Shares of CNMD opened at $58.49 on Friday. The stock’s 50-day moving average price is $65.82 and its 200 day moving average price is $69.10. The company has a quick ratio of 1.06, a current ratio of 2.30 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 1.83 and a beta of 1.53. CONMED Co. has a 12-month low of $55.22 and a 12-month high of $85.28.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, February 5th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.14. CONMED had a return on equity of 14.31% and a net margin of 10.13%. As a group, research analysts predict that CONMED Co. will post 4.35 earnings per share for the current year.

CONMED Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 4th. Investors of record on Friday, March 14th will be paid a $0.20 dividend. The ex-dividend date is Friday, March 14th. This represents a $0.80 dividend on an annualized basis and a yield of 1.37%. CONMED’s payout ratio is currently 18.87%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of CONMED from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Needham & Company LLC decreased their price target on shares of CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a report on Thursday, February 6th. JPMorgan Chase & Co. downgraded CONMED from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $70.00 in a research report on Thursday, February 6th. Finally, Wells Fargo & Company cut their price objective on CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a research report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.20.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.